MS and Demyelinating Disorders

Neurology experts discuss safety data for BTKIs.

Jiwon Oh, MD, PhD, FRCPC, provides an overview of phase II results of tolebrutinib for the treatment of multiple sclerosis.

A recently published study revealed that speech markers can have a high accuracy in distinguishing between neurodegenerative diseases and healthy speech, emphasizing the significance of speech analysis in disease assessment.

A recent study conducted across 11 centers globally challenged the assumption that cognitive rehabilitation and exercise synergistically benefit patients with progressive multiple sclerosis.

Insurance coverage or cost was considered a barrier to prescribing novel NMOSD treatments in 42% of respondents, with the highest rate seen in eculizumab.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending November 18, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 17, 2023.

The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center detailed the difficulties with discussing neuroimmune disorders with newly diagnosed patients, including those who may not speak English. [WATCH TIME: 3 minutes]

The multiple sclerosis (MS) experts advise health care providers on how to impact the early onset of disease progression and prevent neurodegeneration in patients with MS.

The neurologists discuss strategies to improve the cognitive health of patients with multiple sclerosis through physical and mental health multidisciplinary care.

Most of the studies included highlighted the increasing level of difficulty in all exercises performed and that the transition from one kinematic protocol to the other depended on the patient’s rate of improvement.

The associate professor in the department of neurology and neurosurgery at McGill University discussed results from a study on the long-term use of continuous positive airway pressure treatment among patients with multiple sclerosis and sleep apnea presented at MSMilan 2023. [WATCH TIME: 5 minutes]

A recent meta-analysis on tocilizumab in neuromyelitis optica spectrum disorder (NMOSD) emphasized its effectiveness in reducing relapse rates and improving patient function, with patient-specific factors influencing outcomes.

The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center provided perspective on the patient-clinician relationships and the need to educate clinicians about the impacts of rare neuroimmune disorders in Spanish-speaking communities. [WATCH TIME: 3 minutes]

Neurofilament light, a marker of neuroaxonal damage, is correlated with increased levels of disease progression and clinical relapses.

Amit Bar-Or, MD, FRCPC, summarizes fenebrutinib phase II results for the treatment of multiple sclerosis.

Patrick Vermersch, MD, PhD, summarizes phase II clinical trial of evobrutinib for the treatment of multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Patients with multiple sclerosis (MS) showed cognitive improvements with frontal theta-transcranial alternating current stimulation (tACS), suggesting its potential as a tolerable and beneficial intervention.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 10, 2023.

Catch up on any of the neurology news headlines you may have missed over the course of October 2023, compiled all into one place by the NeurologyLive® team.

The phase 2 EMBOLD study on ATA188, an allogenic T-cell immunotherapy for non-active progressive multiple sclerosis, did not meet its primary endpoint of confirmed disability improvement after 12 months of treatment.

The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.

Dr Bruce Hughes and Dr Robert Naismith recommend assessments to aid physicians in evaluating and maintaining the cognitive health of patients with multiple sclerosis.